RESUMEN
The pharmacokinetics and metabolism of reparixin (formerly repertaxin), a potent and specific inhibitor of the chemokine CXCL8, were investigated in rats and dogs after intravenous administration of [14C]-reparixin L-lysine salt. Protein binding of reparixin was investigated in vitro in rat, dog, rabbit, cynomolgus monkey and human plasma. Plasma protein binding of reparixin was >99% in the laboratory animals and humans up to 50 microg ml-1, but lower at higher concentrations. Although radioactivity was rapidly distributed into rat tissues, Vss was low (about 0.15 l kg-1) in both rat and dog. Nevertheless, reparixin was more rapidly eliminated in rats (t1/2 approximately 0.5 h) than in dogs (t1/2 approximately 10 h). Systemic exposure in dog was due primarily to parent drug, but metabolites played a more prominent role in rat. Oxidation of the isobutyl side-chain was the major metabolic pathway in rat, whereas hydrolysis of the amide bond predominated in dog. Urinary excretion, which accounted for 80-82% of the radioactive dose, was the major route of elimination in both species, and biotransformation of reparixin was complete before excretion.
Asunto(s)
Quimiocinas CXC/antagonistas & inhibidores , Sulfonamidas/farmacocinética , Animales , Biotransformación , Isótopos de Carbono/administración & dosificación , Isótopos de Carbono/farmacocinética , Isótopos de Carbono/orina , Quimiocinas CXC/metabolismo , Perros , Femenino , Humanos , Inyecciones Intravenosas , Macaca fascicularis , Masculino , Oxidación-Reducción , Plasma/metabolismo , Conejos , Ratas , Ratas Sprague-Dawley , Especificidad de la Especie , Sulfonamidas/administración & dosificación , Sulfonamidas/orinaRESUMEN
Ketoprofen lysine salt(Artrosilene injectable solution) is a non-steroidal anti-inflammatory agent frequently administered by slow intravenous infusion with portable elastomeric infusion systems in association regimen with other analgesic drugs. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt(Artrosilene injectable solution) and other injectable drugs frequently used in association, such as tramadol hydrochloride, keterolac tromethamine and morphine hydrochloride, into the Infusor LV5, Baxter elastomeric infusion system. Physicochemical properties of drug mixture, including colour, clarity, pH and drug content were observed or measured by a reversed-phase HPLC method with UV detection, before and after (up to 7 days) mixing at room temperature and under light protection. The results obtained demonstrated the physicochemical compatibility of ketoprofen lysine salt(Artrosilene injectable solution) with all drug formulations at every tested mixing ratios into Baxer Infusor LV5 infusion devices.
Asunto(s)
Antiinflamatorios no Esteroideos/química , Cetoprofeno/análogos & derivados , Lisina/análogos & derivados , Analgésicos Opioides/análisis , Analgésicos Opioides/química , Antiinflamatorios no Esteroideos/análisis , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Color , Combinación de Medicamentos , Incompatibilidad de Medicamentos , Embalaje de Medicamentos , Elastómeros , Concentración de Iones de Hidrógeno , Bombas de Infusión , Cetoprofeno/análisis , Cetoprofeno/química , Ketorolaco Trometamina/análisis , Ketorolaco Trometamina/química , Lisina/análisis , Lisina/química , Morfina/análisis , Morfina/química , Soluciones Farmacéuticas , Tramadol/análisis , Tramadol/químicaRESUMEN
Ketoprofen lysine salt (Oki Fiale, PG060) is a non steroidal anti-inflammatory agent frequently administered by intramuscular route in association regimen with other drugs, such as steroidal anti-inflammatory, muscle relaxant, local anaesthetic and anti-spastic drugs or vitamins. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt (Oki Fiale, PG060) and other injectable drugs frequently used in association. Physicochemical properties of ketoprofen lysine salt mixtures with different drugs, including colour, clarity, pH and drug content were observed or measured before and after (up to 3 hours) mixing at room temperature and under light protection. Results show that the association of Oki Fiale (PG060) with different drugs does not cause, up to three hours from mixing, any significant variation in the physicochemical parameters mentioned above. In conclusion, the results obtained demonstrated the physicochemical compatibility of Ketoprofen lysine salt (Oki Fiale, PG060) with several injectable drugs, except for Spasmex fiale (chemical incompatibility) and Xylocaina Astra 2% iniettabile mixed whit a volume ratio of 2/1 (physical incompatibility).
Asunto(s)
Antiinflamatorios no Esteroideos/química , Cetoprofeno/química , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Combinación de Medicamentos , Espectrofotometría UltravioletaRESUMEN
Ketoprofen lysine salt (Artrosilene Fiale), a non steroidal anti-inflammatory agent, is frequently administered in association regimen with other drugs, such as steroidal anti-inflammatory, muscle relaxant, local anaesthetic and anti-spastic drugs or vitamins. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt (Artrosilene Fiale) and other injectable drugs frequently used in association. Physicochemical properties of ketoprofen lysine salt mixtures with different drugs, including colour, clarity, pH and drug content were observed or measured before and after (up to 3 hours) mixing at room temperature and under light protection. Results show that the association of Artrosilene Fiale with different drugs and vitamins does not cause, up to three hours f rom mixing, any significant variation in thephysicochemical parameters mentioned above, except for the association with Benexor B12 where a persistent phase separation occurs. In conclusion the results obtained demonstrated the physicochemical compatibility of Ketoprofen lysine salt (Artrosilene Fiale) with diverse drugs and vitamins, with a single exception.
Asunto(s)
Antiinflamatorios no Esteroideos/química , Cetoprofeno/química , Lisina/química , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Combinación de Medicamentos , Concentración de Iones de Hidrógeno , Cetoprofeno/análogos & derivados , Lisina/análogos & derivados , Vitaminas/químicaRESUMEN
In the search for a new class of bone-sparing agents for treating osteopenic disorders, we hypothesized that tartronic acid derivatives, sharing the chemical characteristics both of bisphosphonates and of Gla residues contained in matrix proteins such as osteocalcin, could positively affect bone metabolism. A series of tartronates was therefore tested for their ability to affect bone metabolism. In vitro resorption tests were performed examining pit formation by freshly isolated rat and rabbit osteoclasts plated onto bone slices and exposed to the drugs for 48 h. Tartronates bearing a linear side-chain (DF 1222 and DF 1363A) were the most effective in inhibiting pit excavation in the pM-nM range. Tartronates did not affect osteoclast viability, number, adhesion, or tartrate resistant acid phosphatase activity. Transient cell retraction was observed in osteoclasts plated onto glass and exposed to DF 1222. The maximal effect was seen in cells treated for 4 h at a concentration of 1 pM. DF 1222 accelerated mineralization in cultures of periosteal cells without affecting other osteoblast-like functions. This product was therefore tested in vivo in ovariectomized mice. Bone mass in femur was evaluated, by ash gravimetry, 21 days after ovariectomy. Unfortunately, DF 1222, the most active of tartronates in vitro, was inactive in this test because of its high hydrophilicity and the subsequent too short residence time. On the contrary, its tetrahydropyranyl ether derivative, DF 1363A, endowed with a significantly higher lipophilicity, showed a dose-dependent bone-sparing effect when administered subcutaneously at 10, 30, and 100 mg/kg/die, thus confirming the activity seen in in vitro tests. Because of their feasible parallel effect on both bone resorption and formation, tartronate derivatives may be tested to candidate this class of products for clinical studies.
Asunto(s)
Enfermedades Óseas Metabólicas/tratamiento farmacológico , Huesos/efectos de los fármacos , Huesos/metabolismo , Tartronatos/farmacología , Animales , Biomarcadores/análisis , Densidad Ósea/efectos de los fármacos , Resorción Ósea/tratamiento farmacológico , Calcitriol/farmacología , Calcio/metabolismo , Bovinos , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Técnicas In Vitro , Lactante , Ratones , Ratones Endogámicos C3H , Osteoclastos/efectos de los fármacos , Osteoclastos/metabolismo , Osteogénesis/efectos de los fármacos , Conejos , Ratas , Tartronatos/químicaRESUMEN
The determination of S-carboxymethyl-(R)-cysteine (SCMC) in human plasma during extended bioequivalence studies demands a rapid, accurate and selective assay technique. A liquid chromatographic/mass spectrometric method was developed which involves rough protein precipitation followed by high-performance liquid chromatographic separation with an ion-exchange column and atmospheric pressure ionization (API) mass spectrometric detection, with the instrument operating with electrospray ionization (ESI) and in the selected-ion monitoring mode. The drug and the internal standard S-[(R)-1-carboxyethyl]-(R)-cysteine (SCEC) are detected by focusing the first quadrupole of the triple stage system on MH+ ions, thus permitting elimination of endogenous interfering substances and allowing a detection limit of 0.05 microgram ml-1. The chromatographic run time is 16 min and the method has sufficient sensitivity, precision, accuracy and selectivity for routine analyses of clinical plasma samples containing SCMC at concentrations in the range 0.2-20 micrograms ml-1. In summary, this LC/MS-based assay of SCMC demonstrates advantages of easy sample preparation, low limit of quantification (200 ng per ml of human plasma) without any derivatization step, high specificity and rapid sample analysis with an overall throughput of more than 60 analyses per day.
Asunto(s)
Carbocisteína/sangre , Expectorantes/análisis , Calibración , Cromatografía Líquida de Alta Presión , Cromatografía por Intercambio Iónico , Humanos , Espectrometría de Masas , Estándares de Referencia , Espectrofotometría UltravioletaRESUMEN
The single amino acid replacement of 2',6'-dimethyl-L-tyrosine in deltorphin B (H-Dmt-D-Ala-Phe-Glu-Val-Val-Gly-NH2) yielded high affinity for mu- and delta-binding sites. [Dmt1]Deltorphin B lacks activity at kappa-opioid binding sites. Bioactivity in vitro with guinea-pig ileum confirmed that [Dmt1]deltorphin B interacted with mu-opioid receptors by reducing electrically induced contractions in a naloxone-reversible manner and was 150-fold more potent than morphine and comparable to [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAGO). The inhibition of spontaneous contractions of rabbit jejunum provided evidence for delta-opioid receptor interaction. Analgesia (hot plate and tail flick tests) revealed that [Dmt1]deltorphin B was 180- to 200-fold more potent than morphine. Pretreatment with naloxone, naltrindole or H-Dmt-Tic-Ala-OH (a highly selective delta-opioid receptor antagonist) prevented [Dmt1]deltorphin B antinociception. Thus, [Dmt1]deltorphin B exhibited remarkably high dual affinity and bioactivity toward delta- and mu-opioid receptors.
Asunto(s)
Contracción Muscular/efectos de los fármacos , Naloxona/farmacología , Naltrexona/análogos & derivados , Antagonistas de Narcóticos/farmacología , Oligopéptidos/metabolismo , Umbral del Dolor/efectos de los fármacos , Receptores Opioides delta/metabolismo , Receptores Opioides mu/metabolismo , Animales , Ratones , Naltrexona/farmacología , Oligopéptidos/química , Oligopéptidos/farmacología , Conejos , Ratas , Receptores Opioides delta/efectos de los fármacos , Receptores Opioides mu/efectos de los fármacosRESUMEN
In this study, we define calmodulin binding sites of skeletal, cardiac, and brain ryanodine receptor (RYR) Ca2+ channels. Cardiac and brain RYR peptides corresponding to the calmodulin binding sites present in the skeletal RYR [Menegazzi, P., et al. (1994) Biochemistry 33, 9078-9084] were synthesized, and their interaction with calmodulin was monitored by fluorescent techniques. The central portions of the skeletal, cardiac, and brain RYR protomers display one high (CaM1; Kd ranging between 2.7 and 10.2 nM) and one low affinity (CaM2; Kd ranging between 116 and 142 nM) calmodulin binding site. Depending on the RYR model having 4 or 12 transmembrane segments, a third calmodulin binding site (CaM3) was identified a few residues upstream from the putative transmembrane segment M1 or M5. Its affinity for calmodulin varied between the RYR isoforms: the cardiac RYR CaM3 displays a high affinity (9.09 +/- 1.0 nM, n = 5), while the skeletal and brain RYR CaM3 have low affinity, the lowest affinity being displayed by the brain isoform (234 +/- 39 nM, n = 3). The RYRs calmodulin binding site CaM1 encompasses the sequence Arg-His-Arg-Val(Ile)-Ser-Leu, which is phosphorylated in vitro by the catalytic subunit of the cAMP-dependent protein kinase. Phosphorylation of RYR PM1 peptides occurs on the Ser, corresponding to amino acid number 2919, 3020, and 3055 of the brain, cardiac, and skeletal RYR protomers, respectively. We found that phosphorylation of the RYR PM1 peptides was inhibited by calmodulin binding and that the formation of the PM1 peptide-calmodulin complex was inhibited by peptide phosphorylation. These data indicate that the effect of calmodulin binding to RYR CaM1 may be regulated by the phosphorylation state of the Ser residue localized within the sequence Arg-His-Arg-Val(Ile)-Ser-Leu.